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Abstract
Comorbidity is an issue of growing importance due to changing demographics and the increasing 
number of adults over the age of 65 with cancer. The best approach to the clinical management 
and decision-making in older adults with comorbid conditions remains unclear. In May 2015, the 
Cancer and Aging Research Group in collaboration with the National Cancer Institute and 
National Institute on Aging met to discuss the design and implementation of intervention studies 
in older adults with cancer. A presentation and discussion on comorbidity measurement, 
interventions, and future research was included. In this article we discuss the relevance of 
comorbidities in cancer, examine the commonly used tools to measure comorbidity, and discuss 
the future direction of comorbidity research. Incorporating standardized comorbidity 
measurement, relaxing clinical trial eligibility criteria, and utilizing novel trial designs are critical 
to developing a larger and more generalizable evidence base to guide the management of these 
patients. Creating or adapting comorbidity management strategies for use in older adults with 
cancer is necessary to define optimal care for this growing population.
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Introduction
Comorbidity, defined as a medical condition that exists along with an index condition, is an 
issue of growing importance due to changing demographics and the increasing number of 
adults over the age of 65 with cancer.(1, 2) In a study of Medicare beneficiaries, over two-
thirds had two or more medical conditions and nearly 25% of participants had four or more 
conditions.(3) Figure 1 shows the prevalence of 10 common co-occurring chronic conditions 
among Medicare beneficiaries 65 years of age or older with various cancer types. While the 
prevalence of multiple chronic illnesses in older adults is rapidly increasing in the United 
States,(3) older adults with cancer have an even higher prevalence of comorbidity than an 
age-matched control group without cancer.(4) More than half of all older adults with cancer 
have at least one comorbidity that may impact their cancer treatment.(5) The frequent 
practice of excluding patients with common comorbid illnesses and the lack of systematic 
measurement of comorbidities in cancer clinical trials limit the evidence base for making 
informed decisions regarding these patients. The best approach to the clinical management 
and decision-making in older adults with comorbid conditions remains unclear.(6) Most 
clinical practice guidelines, in cancer and elsewhere, are single disease focused, limiting 
their application in patients with multiple comorbid illnesses.(7) Recognizing and managing 
comorbidities in older adults with cancer will become an increasingly routine issue for 
oncologists and may in fact already be the rule rather than the exception.
Although the term multimorbidity is frequently used interchangeably with comorbidity, we 
define multimorbidity as the presence of several comorbid illnesses in which one single 
condition is not the predominant focus. As this article is specifically addressing 
comorbidities within the context of cancer, we will be using the term comorbidity regardless 
of the number of comorbid illnesses. At the recent U-13 conference “Design and 
Implementation of Intervention Studies to Improve or Maintain Quality of Survivorship in 
Older and/or Frail Adults with Cancer”, a session was included on comorbidity 
measurement, interventions, and future research. Based on the discussion from the U13 
conference, this article will:
1. Discuss the relevance of comorbidities in cancer
2. Examine the commonly used tools to measure comorbidity
3. Discuss the future direction of comorbidity research and key 
methodological considerations
Relevance in Cancer
Over the last decade, the importance of comorbidity in oncology has become clearer. 
Comorbid illnesses impact cancer in various ways. They serve as confounders that 
complicate the diagnosis and treatment of cancer, they mediate cancer or cancer treatment 
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effects, and pose competing risks for morbidity and mortality.(2) The influence of comorbid 
conditions on cancer can vary dramatically as the comorbid illnesses themselves encompass 
a heterogeneous group of conditions ranging in number and severity. This multifaceted 
effect of comorbidities only further complicates the already complex decision-making in 
older patients with cancer. Incorporating comorbid conditions into cancer treatment 
decision-making has become a vital component of understanding the risks and benefits of 
treatments for an individual patient, especially an older one.
Association of comorbidity with survival
Most observational studies have found that patients with cancer and comorbidities have 
poorer survival than those without comorbidity.(8) While survival rates vary by cancer type, 
generally, patients with higher rates of comorbidity have 1.1 to 5.8-fold higher mortality 
risk.(8) In a recent cohort study of 6,325 older adults with cancer, the 5-year all-cause 
mortality increased with higher levels of comorbidity in a variety of different cancers 
including breast, lung, colorectal, prostate, and ovarian (e.g., hazard ratio for severe 
comorbidity in prostate cancer was 2.14, 95% CI 1.65–2.77).(4) The presence of moderate 
to severe comorbidities is of greatest prognostic importance among patients with localized 
and potentially curable cancer, such as early-stage breast or prostate cancer; in contrast, 
comorbidities have little impact on overall survival in more lethal and aggressive cancers 
where mortality is dominated by the primary disease.(9)
Impact of comorbidity on cancer risk, recurrence, and stage
Comorbid conditions impact cancer risk, cancer recurrence, and influence the stage at 
diagnosis. Patients with obesity, diabetes, end-stage renal disease, or immunodeficiencies are 
at an elevated risk for developing cancer.(10–13) Conversely, many of the treatments for 
common comorbidities, such as aspirin, statins, metformin, and anti-inflammatory agents, 
may help decrease cancer incidence and risk of recurrence.(14–18) Several studies have 
found a higher prevalence of comorbidity in early stage cancers.(8) This increase in 
comorbid conditions among patients with early stage cancer may be in part related to the 
frequent healthcare utilization and monitoring required for treatment of these conditions. A 
study using Surveillance, Epidemiology, and End Results (SEER)-Medicare data showed 
that comorbidity burden was associated with higher rates of mammography and with an 
earlier stage of diagnosis in breast cancer patients.(19) This same study also found that a 
group of more serious comorbid conditions, such as severe heart failure and end-stage 
pulmonary disease, were associated with less mammography screening and later stage at 
diagnosis.
Association of comorbidity with toxicity
Patients with cancer and comorbid conditions are at an increased risk of major toxicity and 
hospitalization due to chemotherapy-related toxicities.(20–22) In a study evaluating 
chemotherapy toxicities in older adults undergoing adjuvant chemotherapy for breast cancer, 
the risk of toxicity depended more on the presence of comorbidity than on age.(22) Older 
adults with a Charlson Comorbidity Index (CCI) score of ≥1 were three times more likely to 
experience grade 3 or 4 non-hematologic toxicities. Conversely, two recently developed 
chemotherapy toxicity calculators for use in older adults do not include comorbidities, as 
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there was no significant association of comorbidities with the incidence of grade 3 or 4 
toxicity when controlling for functional status, suggesting the impact of comorbidities may 
be via their effect on function.(23, 24) Similarly, in a recent secondary analysis of 
comorbidity in older adults with breast cancer, no association with toxicity was found.(25) 
In a study evaluating chemotherapy related hospitalizations, severe comorbid illness (CCI 
score ≥3) increased the risk of hospitalization nearly 10 fold and was the strongest predictor 
of hospitalization.(21) Moreover, patients with comorbidities are less likely to complete 
chemotherapy compared to patients without comorbidity.(26) Several studies have shown 
that comorbidity is associated with decreased rates of completing chemotherapy in several 
cancer types. However, whether this is a direct result of increased toxicity, decreased 
functional status, or is related to poor adherence is unclear.(8) The increased risk of toxicity 
in adults with comorbidities may in part be related to the increased use of medications for 
comorbid conditions and medication interactions; however, a recent study showed no 
association between the number of daily medications or potentially inappropriate 
medications in older adults undergoing chemotherapy.(27)
The differing rates of toxicity observed in patients with comorbid illnesses do not fully 
explain the differences in overall survival seen in some studies. In a large study of older 
adults with colorectal cancer undergoing adjuvant chemotherapy, the presence of diabetes 
had a significant impact on long-term survival (median survival of 6.0 versus 11.3 years) that 
was independent of treatment-related toxicity.(28) In addition, as cancer treatment can result 
in new comorbidities, such as cardiac toxicity, neuropathy, or renal impairment, it is 
important to distinguish pre-treatment comorbid conditions from those that develop as a 
consequence of toxicity.(29, 30)
Impact of comorbidities on cancer treatment decisions
As comorbidities alter both the risk and benefit from cancer treatments, they can impact the 
risk/benefit balance of many treatment decisions. This may be why patients with 
comorbidities are less likely to receive adjuvant chemotherapy.(31–34) In a study using 
SEER-Medicare database, older adults with resected stage III colorectal cancer with 
comorbidities were less likely to be referred to a medical oncologist for consideration of 
adjuvant chemotherapy and less likely to be given chemotherapy when seen by an 
oncologist.(33) The presence of comorbidities is one of the most frequent reasons for non-
receipt of cancer treatment cited in the medical chart.(35, 36) Although chronic conditions 
appear to be a strong barrier to the receipt of adjuvant chemotherapy, some studies have 
shown a similar survival benefit with or without many common comorbid illnesses.(37) 
Reduced chemotherapy treatment and decreased adjuvant referral patterns may represent 
thoughtful and appropriate treatment decisions on the part of both physicians and/or patients 
based on the presence of comorbidities and limited life expectances. However, these 
decisions may also represent an inappropriate reflection of physician bias based on 
chronologic age.
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Measuring Comorbidity
Given the overall impact of comorbidities in cancer care, there is a compelling need to 
measure comorbidities in research and clinical settings. Standardized comorbidity 
assessment should be considered as a common data element for every patient. Without the 
systematic incorporation of comorbid conditions in cancer decision-making, oncologists 
may overestimate cancer risk, overestimate the benefits of cancer treatment, and will be 
unable to distinguish toxicity from comorbidity. Over the last decade a growing number of 
studies have included measures of comorbidity, but with little consistency in measurement 
and a resulting lack of comparability across research settings.(38) Due to the diverse nature 
of possible comorbid diseases, a systematic assessment of every conceivable comorbid 
illness and degree of severity would easily create an unmanageable amount of information; 
therefore, some selection and pooling of information is necessary.(39) Many methods for 
assessing comorbid illnesses are available and no gold standard approach exists (see table 1 
for a selected list of available instruments).
In a recent review of methods used to measure comorbidity in cancer populations, 21 distinct 
approaches were identified.(38) These methods varied from simple counts of individual 
conditions to weighted indices. The approach of measuring the prevalence of individual 
conditions and either using them separately or summing the number of conditions, is the 
simplest method.(40, 41) This method has been used in the development of a range of 
comorbidity indexes in several different cancer types with a variable number of conditions 
included, ranging from 7 to 102.(38) Inclusion and exclusion of comorbid conditions were 
based on clinical judgement, on literature in the area, on empirical analysis, or on a 
combination thereof. Notably, many of these exclude obesity as an identified comorbidity. 
As many of these indices combine conditions into a single unweighted measure of 
comorbidity, the implicit assumption is made that all conditions are equally important in 
relationship to outcomes.
In contrast, a weighted index assigns importance to individual conditions according to their 
relative impact on key outcomes and attempts to account for the differential impact of 
certain conditions on outcomes. The most frequently cited weighted index in the literature 
and the first example of this approach was the Charlson Comorbidity Index (CCI).(42) The 
CCI was developed by Mary Charlson and colleagues in 1987 using data from hospital notes 
on an internal medicine service. Charlson et al analyzed mortality at 1 year as a function of 
various comorbidities. The resulting Index was a list of 19 conditions that are weighted from 
1 to 6 according to their relative risk of death. The total score is calculated and can be then 
collapsed into four categories: 0, 1–2, 3–4, and ≥5. Algorithms have been developed to 
calculate Charlson scores from the use of administrative data and the index has been 
reweighted using administrative claims to account for advances in medical care.(43, 44) 
Questionnaires have also been developed that utilize patient self-report to calculate Charlson 
scores.(45) The CCI is the basis of other comorbidity indices including the NCI 
Comorbidity Index that utilizes a subset of the same conditions and weights conditions using 
beta coefficients (rather than relative risk used by the CCI).(46, 47)
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As some comorbid conditions are more prevalent in certain cancers — for instance, COPD 
in lung cancer — and the impact of comorbid illnesses is often specific to the cancer type, 
weighted indices have been developed for use in particular cancers.(48–50) For example, the 
Washington University Head and Neck Comorbidity Index (WUHNCI) was developed for 
use in patients with head and neck cancer and includes seven comorbid conditions that were 
significantly related to survival in these patients.(49) Similarly, a hematopoietic cell 
transplant (HCT)-specific comorbidity index has been developed to improve the sensitivity 
and specificity for predicting risks of non-relapse mortality after HCT.(50)
Another commonly used approach to comorbidity measurement is to assess the impact of 
comorbid illnesses on the function of body organs or systems.(38) The first example of this 
method was the Cumulative Illness Rating Scale (CIRS) that classifies comorbidities by 
organ system affected and rates comorbidities according to their severity from 0 to 4.(51) 
Scores can be summarized as a total score, as a total number of categories involved, as a 
mean score, or as a number of grade 3 or 4 diseases.(52) The Kaplan-Feinstein Index (KFI) 
also groups conditions into 12 categories each with a severity rating of 0–3.(53) Although 
the KFI was originally developed in a group of 188 men with diabetes, it has subsequently 
been used in a number of cancer-related studies.(54, 55)
The Index of Coexistent Diseases (ICED) combines two dimensions of comorbid illness: a 
measure of comorbid disease severity assessed by organ system and the degree of physical 
impairment.(56) The ICED has been most widely used to study the correlation of 
comorbidity with treatment patterns and survival.(52) Lastly, the Older Americans 
Resources and Services Questionnaire (OARS) Physical Health subscale obtains information 
on 14 specific comorbid conditions and includes the degree that each interferes with the 
participant’s activities.(57)
Choosing the “right” comorbidity measurement tool depends on the specific research 
question and/or the clinical setting. Some tools are better suited for use in the clinical setting 
while others are more useful for retrospective review or for use with administrative claims 
data. Some comorbidity measures are developed and validated to predict mortality, which 
may or may not be helpful in a study of healthcare utilization. Ultimately, what is most 
important is not how comorbid illnesses are measured, but that the comorbidities are 
measured and considered in some way (although, as we discuss below, standardization of 
comorbidity assessment is an important goal for clinical trials). Furthermore, the timing of 
the measurement is also important as comorbidities can also be a direct consequence of 
cancer treatment.(58) The method of measurement used must also be transparent in reports 
of research. Several detailed reviews of comorbidity measurement can be consulted for an 
examination of available measures.(38, 52)
In the context of prospective clinical trial design, a concerted effort is needed to standardize 
comorbidity measurement. The lack of comorbidity measurement in ongoing clinical trials 
tremendously limits our understanding of the impact of comorbid illnesses. An estimate of 
the burden of comorbidity is needed to better characterize study participants, and analyses of 
trial results in subgroups of individuals with comorbidities would improve our ability to 
extrapolate findings to older patients. Even in the trials that incorporate comorbidity 
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measurement, the lack of standardization limits our ability to compare across trials. A 
minimum data set that includes some measure of comorbidity is necessary across oncology 
trials.
Studying Comorbidity
Many significant research gaps exist in the cancer care of individuals with comorbid 
conditions. Incorporating and developing standardized comorbidity assessments in clinical 
trials, as described above, is an important first step. Reducing the common eligibility criteria 
that limit the participation of older adults with comorbid conditions is necessary to improve 
the evidence base for treating these patients. The use of innovative trial designs can help to 
better incorporate comorbidities into clinical trials. Lastly, the development and adaption of 
comorbidity interventions and management strategies is necessary to elucidate best 
practices.
Common eligibility criteria used in clinical trials lead to the exclusion of older adults, 
particularly those with comorbid illnesses.(59) Due to these strict eligibility criteria, study 
populations rarely are representative of the population at large with the given condition. The 
response of older adults to cancer treatment is heterogeneous and may be different from 
younger patients, due not only to age-related changes in organ function, but also to the 
higher prevalence of comorbidity and the use of concomitant medications. There is 
increasing evidence that relaxed eligibility criteria can be implemented without reducing 
scientific rigor.(60) Less stringent criteria will ultimately decrease barriers to accrual and 
lead to more generalizable research.(61) Future studies should include populations that 
reflect the age and health profiles of the patients with the disease,(62) and this can only be 
achieved with more inclusive eligibility criteria.
Innovative trial designs allow investigators to include larger numbers of patients with high 
levels of comorbidities. Clinical trial designs have progressed from testing of two treatment 
options in homogenous cohorts to more innovative and pragmatic designs that purposefully 
allow the inclusion of greater numbers of complex patients. Randomization balances the 
observed and unobserved characteristics (including comorbidities) across treatment groups; 
however, these complex, heterogeneous groups have greater variability for the treatment 
effect, which effectively requires greater sample sizes for the same power to detect 
differences. The advantage of adaptive randomization techniques is that patients may be 
allocated at a higher probability to treatment arms that are more likely to be favorable, 
particularly in trials with early endpoints (e.g. biomarkers).(63) This approach assumes that 
the trial is testing for the most favorable therapy regardless of comorbidities. If there is 
knowledge a priori that therapeutic options might differ by the presence of specific 
comorbidities, then trials should be designed for patients with and without those 
comorbidities.
Platform trials focus on studying the disease for which new therapies are continually 
developed and tested. This new type of trial design belongs to the family of adaptive 
randomization designs and is intended to continue beyond the evaluation of the initial 
treatments to investigate treatment combinations, as well as to quantify differences in 
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treatment effects in subgroups while treating patients as effectively as possible within the 
trial.(64) The i-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic Response 
With Imaging and Molecular Analysis) breast cancer trial is an example of a trial that 
utilizes an adaptive, modular design process for the purpose of screening phase II agents 
concurrently in women with early-stage breast cancer.(65) Sequential, multiple assignment, 
randomized trial (SMART) designs also are being used to construct adaptive interventions 
and allow augmentation of initial treatment for non-responders.(66) This approach may be 
modified for cohorts with comorbidities and does not require endpoints to occur as quickly 
as adaptive randomization designs. Lastly, standardly-tailored designs have been used in 
geriatrics for decades to evaluate multicomponent interventions.(67, 68) These designs 
randomize participants into active treatment or usual care and do not require that all subjects 
be eligible for every interventional component. Those in the active treatment arm receive per 
protocol therapies for all conditions present that the trial is testing. This approach yields an 
overall intervention effect and is fully flexible to heterogeneous cohorts.
Another effective avenue for studying comorbidities is through the use of comparative-
effectiveness research (CER). CER utilizes existing health care information to evaluate 
which treatments or interventions work best, for whom, and in what circumstances. Many 
large databases exist or are planned with information on a diverse range of older adults with 
cancer and comorbidities, such as the ORIEN network or the SEER-Medicare databases. 
These administrative databases provide a forest view of comorbidities and often lack 
granularity about comorbid conditions (such as severity and impact on function) and other 
important geriatric assessment variables. Although CER data are not always collected 
systematically and must be interpreted with caution to minimize the risk of drawing 
erroneous conclusions, CER can be a powerful tool to produce inexpensive and quick results 
using data from larger, more diverse populations.(59)
Not only are more clinical trials needed that include patients with comorbid conditions and 
incorporate systematic comorbidity measurement, there is also a need to develop and study 
comorbidity interventions. Research to date on comorbidities in oncology has primarily 
focused on descriptive epidemiology and impact assessment with limited exploration of 
potential interventions. There are a limited number of studies on comorbidities even in non-
cancer patients.(69) Implementing conceptual frameworks such as the American Geriatrics 
Society’s Guiding Principles for the Care of Older Adults with Multimorbidity in oncology 
patients may be an ideal first step.(70) These five guiding principles (see figure 2) were 
developed from a structured review of the literature and expert consensus and provide a 
stepwise approach to management of older patients with multiple comorbidities. The 
challenge in older oncology patients, in particular, is operationalizing these principles and 
adapting them to guide oncology decision-making.(71) Developing new care models and 
flexible coordinated care strategies is also necessary given the breadth of potential comorbid 
illnesses present in older adults with cancer. Systematically testing these new models and 
strategies in older cancer patients with comorbidity is required to ultimately provide the 
evidence to change cancer care for these complex patients.
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Conclusions
As the population continues to age and the prevalence of comorbidity in oncology grows, 
developing a better understanding of the impact of comorbid illnesses on cancer care and 
management strategies will be vital. Although oncologists and patients are primarily focused 
on cancer and its treatment, the implications and management of comorbidities will become 
increasingly important. Incorporating standardized comorbidity measurement, relaxing 
clinical trial eligibility criteria, and utilizing novel trial designs are critical to developing a 
larger, more generalizable evidence base to guide the management of these patients. 
Creating comorbidity management strategies for use in older adults with cancer is necessary 
to provide optimal care for this growing population.
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Figure 1. 
Prevalence of 10 common co-occurring chronic conditions among Medicare beneficiaries 65 
years of age or older with various cancer types as the index condition. This figure includes 
the 10 most prevalent comorbidities, out of a set of 28 conditions, among beneficiaries with 
each individual cancer type as identified by diagnoses codes in Medicare claims data. This 
figure is based upon data previously published as part of ASCO Clinical Practice Guidelines.
(72–75) (Intended for color on the web and black/white in print)
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Figure 2. 
Guiding principles for the care of older adults with multimorbidity.
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